Literature DB >> 17913661

Management of solid tumours in organ-transplant recipients.

Thankamma V Ajithkumar1, Christine A Parkinson, Andrew Butler, Helen M Hatcher.   

Abstract

Malignancy is a well-recognised complication of transplantation and can occur de novo, as a recurrence of a pre-existing malignancy, or from transmission of malignancy from the donor. Common de-novo malignancies are those of the skin and the lymphoreticular system. Various solid-organ cancers have also been reported in transplant recipients and each poses a unique management challenge in view of the unusual setting. We review solid-organ cancers in transplant recipients and their management, including surveillance and prevention.

Entities:  

Mesh:

Year:  2007        PMID: 17913661     DOI: 10.1016/S1470-2045(07)70315-7

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


  21 in total

Review 1.  Malignancy after renal transplantation: the role of immunosuppression.

Authors:  Inés Rama; Josep M Grinyó
Journal:  Nat Rev Nephrol       Date:  2010-09       Impact factor: 28.314

Review 2.  Repeat partial nephrectomy: surgical, functional and oncological outcomes.

Authors:  Brian Shuch; W Marston Linehan; Gennady Bratslavsky
Journal:  Curr Opin Urol       Date:  2011-09       Impact factor: 2.309

3.  Malignancy: An Adverse Effect of Immunosuppression.

Authors:  Mrudula Munagala; Anita Phancao
Journal:  Handb Exp Pharmacol       Date:  2022

Review 4.  Emerging Concepts in Managing Malignancy in Kidney Transplant Patients.

Authors:  Brittany Schreiber; Maen Abdelrahim; Ala Abudayyeh; Naoka Murakami
Journal:  Semin Nephrol       Date:  2022-01       Impact factor: 4.472

5.  CXCR3 antagonism impairs the development of donor-reactive, IFN-gamma-producing effectors and prolongs allograft survival.

Authors:  Joshua M Rosenblum; Qi-Wei Zhang; Gerald Siu; Tassie L Collins; Timothy Sullivan; Daniel J Dairaghi; Julio C Medina; Robert L Fairchild
Journal:  Transplantation       Date:  2009-02-15       Impact factor: 4.939

6.  Elevated cutaneous Smad activation associates with enhanced skin tumor susceptibility in organ transplant recipients.

Authors:  Kelly A Harradine; Katie Ridd; Elise F Saunier; Frederic F Clermont; Jesus Perez-Losada; Dan H Moore; Ervin H Epstein; Boris C Bastian; Rosemary J Akhurst
Journal:  Clin Cancer Res       Date:  2009-08-11       Impact factor: 12.531

7.  Donor-reactive CD8 memory T cells infiltrate cardiac allografts within 24-h posttransplant in naive recipients.

Authors:  A D Schenk; T Nozaki; M Rabant; A Valujskikh; R L Fairchild
Journal:  Am J Transplant       Date:  2008-06-18       Impact factor: 8.086

8.  Risk of Thyroid Cancer Among Solid Organ Transplant Recipients.

Authors:  C M Kitahara; E L Yanik; P W Ladenson; B Y Hernandez; C F Lynch; K S Pawlish; E A Engels
Journal:  Am J Transplant       Date:  2017-05-30       Impact factor: 9.369

9.  Clinical outcomes of solid organ transplant recipients with metastatic cancers who are treated with immune checkpoint inhibitors: A single-center analysis.

Authors:  Itunu Owoyemi; Lisa E Vaughan; Collin M Costello; Charat Thongprayoon; Svetomir N Markovic; Joerg Herrmann; Clark C Otley; Timucin Taner; Aaron R Mangold; Nelson Leung; Sandra M Herrmann; Aleksandra Kukla
Journal:  Cancer       Date:  2020-08-12       Impact factor: 6.860

10.  Tumor Recurrence and Graft Survival in Renal Transplant Recipients with a History of Pretransplant Malignancy: A Matched Pair Analysis.

Authors:  Felix Becker; Anne-Sophie Mehdorn; Vasilios Getsopulos; Katharina Schütte-Nütgen; Stefan Reuter; Barbara Suwelack; Andreas Pascher; Jens G Brockmann; Ralf Bahde
Journal:  J Clin Med       Date:  2021-05-27       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.